Nagappan Ashwini, Kalokairinou Louiza, Wexler Anna
University of Pennsylvania.
AJOB Neurosci. 2021 Oct-Dec;12(4):257-269. doi: 10.1080/21507740.2021.1896601. Epub 2021 Mar 24.
Neurotherapies for diagnostics and treatment-such as electroencephalography (EEG) neurofeedback, single-photon emission computerized tomography (SPECT) imaging for neuropsychiatric evaluation, and off-label/experimental uses of brain stimulation-are continuously being offered to the public outside mainstream healthcare settings. Because these neurotherapies share many key features of complementary and alternative medicine (CAM) techniques-and meet the definition of CAM as set out in Kaptchuk and Eisenberg-here we refer to them as "alternative neurotherapies." By explicitly linking these alternative neurotherapy practices under a common conceptual framework, this paper draws attention to, and critically considers, the cross-cutting ethical and legal issues related to the provision of these services. The first section of this paper provides an updated empirical overview of uses of SPECT neuropsychiatric evaluations, EEG neurofeedback, and experimental/off-label forms of brain stimulation. Next, drawing on CAM bioethics scholarship, we highlight the pertinent ethical issues in the alternative neurotherapy context, including the truthful representation of evidence base, marketing to vulnerable populations, potential harms, provider competency, and conflicts of interest. Finally, we consider the principal legal issues at stake for the provision of alternative neurotherapies in the U.S., namely those related to licensing and scope-of-practice considerations. We conclude with recommendations for future research in this domain.
用于诊断和治疗的神经疗法——如脑电图(EEG)神经反馈、用于神经精神评估的单光子发射计算机断层扫描(SPECT)成像以及脑刺激的非标签/实验性应用——不断在主流医疗环境之外向公众提供。由于这些神经疗法具有补充和替代医学(CAM)技术的许多关键特征,并且符合卡普丘克和艾森伯格所提出的CAM定义,因此我们在此将它们称为“替代神经疗法”。通过在一个共同的概念框架下明确地将这些替代神经疗法实践联系起来,本文提请人们关注并批判性地思考与提供这些服务相关的交叉伦理和法律问题。本文的第一部分提供了关于SPECT神经精神评估、EEG神经反馈以及脑刺激的实验性/非标签形式应用的最新实证概述。接下来,借鉴CAM生物伦理学的学术成果,我们突出了替代神经疗法背景下的相关伦理问题,包括证据基础的如实呈现、向弱势群体进行营销、潜在危害、提供者的能力以及利益冲突。最后,我们考虑在美国提供替代神经疗法所涉及的主要法律问题,即那些与许可和执业范围考量相关的问题。我们最后给出了该领域未来研究的建议。